Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more and get updates at SpurTherapeutics.com.
This site will remain live until Q4 2024 as we transition content to our new site.
Our CEO and SVP of Clinical and Medical Affairs speak about healthcare resource use research on men and women living with AMN, as well as SwanBio’s background, pipeline, and culture.
May 17, 2023
Swan’s CSO reflects with Cell & Gene about the gene therapy progress that has been made for rare disease, and areas where progress is still needed.
February 28, 2023
Swan’s CSO joins gene & cell therapy executives to share their outlook on commercial-scale manufacturing and other sector-related trends for 2023.
December 17, 2022
SwanBio’s CEO, Tom Anderson, and Chair, Chris Hollowood, speak with BioCentury’s Associate Editor, Paul Bonanos, about the company’s Series B funding and path forward.
May 18, 2022
SwanBio’s CEO, Tom Anderson, speaks to Senior Healthcare Reporter John George at the Philadelphia Business Journal about the company’s Series B financing round.
May 18, 2022
SwanBio’s CSO speaks to HCPLive about SBT101 preclinical data presented at the Annual Academy of Neurology (AAN) 2022 Annual Meeting. These data build on previous SBT101 research that showed on-target effects and a favorable safety profile with no observed treatment-related adverse events.
April 5, 2022
In honor of Rare Disease Day, this inaugural podcast episode features our Co-Founder and CSO, Karen Kozarsky, Ph.D, discussing adrenomyeloneuropathy and SwanBio’s quest to develop a meaningful treatment.
February 28, 2022
SwanBio Co-Founder and CSO, Karen Kozarsky, Ph.D, describes how we are pioneering a pipeline for genetically defined neurological diseases with a focus on the spinal cord, thanks to our differentiated approach to gene therapy and unique company culture.
September 16, 2021
